Document is current
Any future updates will be listed below
-
Authors
Sandoval, Renata L.
Horiguchi, Miki
Ukaegbu, Chinedu
Furniss, C. Sloane
Uno, Hajime
Syngal, Sapna
Yurgelun, Matthew B.
-
Funding
Funding for this research was provided by:
The Helen Gurley Brown Presidential Initiative
National Institutes of Health (R01CA132829)
The Sweet Family Fund
The Stephani Batchelor and Andrew Robert Whittaker Family Fund for Lynch Syndrome Research
The Lesswitz Fund for Lynch Syndrome
The Terry T. Sweet Fund for Lynch Syndrome
The Rasmussen Family Fund for Colorectal Cancer Research
The Scragg Family Fund
- License Information
-
More Information
Article History
Received: 24 May 2023
Accepted: 24 July 2023
First Online: 12 August 2023
Declarations
:
: This study was approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board. This study was performed in accordance with the principles of the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
: Dr. Uno reports prior consulting/advisory payments from Roche. Dr. Syngal reports prior consulting fees from Myriad Genetics Laboratories, Inc., and inventor/royalties from PREMM model. Dr. Yurgelun reports consulting/scientific advisory board fees and research funding from Janssen Pharmaceuticals as well as payments for peer review services from UpToDate. Drs. Sandoval, Horiguchi, Ukaegbu and Furniss have no financial or non-financial conflicts of interest to declare.
: Preliminary data from this manuscript were presented as an abstract at the Annual Meeting of the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (Nashville, TN) in November 11–13, 2022.
